company background image
MBRX

Moleculin Biotech NasdaqCM:MBRX Stock Report

Last Price

US$1.62

Market Cap

US$46.3m

7D

-4.7%

1Y

-45.5%

Updated

13 Aug, 2022

Data

Company Financials +
MBRX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MBRX Stock Overview

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses.

Moleculin Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Moleculin Biotech
Historical stock prices
Current Share PriceUS$1.62
52 Week HighUS$3.20
52 Week LowUS$1.02
Beta1.78
1 Month Change-3.57%
3 Month Change30.65%
1 Year Change-45.46%
3 Year Change-74.53%
5 Year Change-88.70%
Change since IPO-96.63%

Recent News & Updates

Jul 11
Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Jul 08

Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial

Moleculin Biotech (NASDAQ:MBRX) said preliminary data from the second group of its phase 1a study of WP1122 showed that the COVID-19 drug candidate was safe in healthy people. The second cohort consisted of 8 people who were dosed with 16 mg/kg or placebo in a dose escalation trial of WP1122 in healthy people in the U.K. The company said that based on the overall results in group 2, it deemed the cohort dose as safe and well-tolerated and began its Single Ascending Dose (SAD) group 3 with a dose escalation to 32 mg/kg. "To date, WP1122 has demonstrated no dose escalating stopping criteria, and we look forward to taking the next step in studying the potential of WP1122 for the treatment of certain viral diseases, including COVID-19, and cancers," said Moleculin Chairman and CEO Walter Klemp. The phase 1 trial in total is evaluating WP1122 administered as an oral solution.

Shareholder Returns

MBRXUS BiotechsUS Market
7D-4.7%1.2%3.2%
1Y-45.5%-21.7%-10.1%

Return vs Industry: MBRX underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: MBRX underperformed the US Market which returned -10.1% over the past year.

Price Volatility

Is MBRX's price volatile compared to industry and market?
MBRX volatility
MBRX Average Weekly Movement8.6%
Biotechs Industry Average Movement12.5%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: MBRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: MBRX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201515Wally Klemphttps://www.moleculin.com

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company’s flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies.

Moleculin Biotech Fundamentals Summary

How do Moleculin Biotech's earnings and revenue compare to its market cap?
MBRX fundamental statistics
Market CapUS$46.30m
Earnings (TTM)-US$20.85m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MBRX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$20.85m
Earnings-US$20.85m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.73
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did MBRX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MBRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MBRX?

Other financial metrics that can be useful for relative valuation.

MBRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does MBRX's PB Ratio compare to its peers?

MBRX PB Ratio vs Peers
The above table shows the PB ratio for MBRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.5x
MTEM Molecular Templates
2x-12.2%US$52.8m
CDTX Cidara Therapeutics
n/a34.9%US$44.5m
SNPX Synaptogenix
1.8x1.4%US$50.8m
ACHV Achieve Life Sciences
3.7x62.4%US$48.4m
MBRX Moleculin Biotech
0.7x41.9%US$46.3m

Price-To-Book vs Peers: MBRX is expensive based on its Price-To-Book Ratio (0.7x) compared to the peer average (0.5x).


Price to Earnings Ratio vs Industry

How does MBRX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: MBRX is good value based on its Price-To-Book Ratio (0.7x) compared to the US Biotechs industry average (1.9x)


Price to Book Ratio vs Fair Ratio

What is MBRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MBRX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MBRX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of MBRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MBRX ($1.62) is trading below our estimate of fair value ($69.4)

Significantly Below Fair Value: MBRX is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Moleculin Biotech forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


41.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MBRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MBRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MBRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MBRX is forecast to have no revenue next year.

High Growth Revenue: MBRX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MBRX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Moleculin Biotech performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-15.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MBRX is currently unprofitable.

Growing Profit Margin: MBRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MBRX is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.

Accelerating Growth: Unable to compare MBRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MBRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: MBRX has a negative Return on Equity (-31.42%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Moleculin Biotech's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MBRX's short term assets ($61.3M) exceed its short term liabilities ($5.9M).

Long Term Liabilities: MBRX's short term assets ($61.3M) exceed its long term liabilities ($1.0M).


Debt to Equity History and Analysis

Debt Level: MBRX is debt free.

Reducing Debt: MBRX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MBRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MBRX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 22.4% each year.


Discover healthy companies

Dividend

What is Moleculin Biotech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MBRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MBRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MBRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MBRX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MBRX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Wally Klemp (62 yo)

7.08yrs

Tenure

US$1,987,313

Compensation

Mr. Walter V. Klemp, also known as Wally, founded Moleculin Biotech, Inc. in July 2015 and has been its Chief Executive Officer since July 2015 and President since August 23, 2017. He served as Director at...


CEO Compensation Analysis

Compensation vs Market: Wally's total compensation ($USD1.99M) is above average for companies of similar size in the US market ($USD760.00K).

Compensation vs Earnings: Wally's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MBRX's management team is seasoned and experienced (5.1 years average tenure).


Board Members

Experienced Board: MBRX's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Moleculin Biotech, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Moleculin Biotech, Inc.
  • Ticker: MBRX
  • Exchange: NasdaqCM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$46.297m
  • Shares outstanding: 28.58m
  • Website: https://www.moleculin.com

Number of Employees


Location

  • Moleculin Biotech, Inc.
  • 5300 Memorial Drive
  • Suite 950
  • Houston
  • Texas
  • 77007
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/13 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.